Search
Niflumic acid
go.drugbank.com/drugs/DB04552InvestigationalNiflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.
Categories: Antiinflammatory Preparations, Non-Steroids for Topical UseVintafolide
go.drugbank.com/drugs/DB05168InvestigationalVintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.
AZD-8330
go.drugbank.com/drugs/DB06061InvestigationalAZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival.
Rivanicline
go.drugbank.com/drugs/DB05855ExperimentalIt has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis. … Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype.
NP-50301
go.drugbank.com/drugs/DB05662ExperimentalIt is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals.
FX06
go.drugbank.com/drugs/DB05685InvestigationalIt is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.
Glofitamab
go.drugbank.com/drugs/DB16371ApprovedInvestigational], [vincristine], [prednisone])[L45763] - despite this, as many as 40% of patients will experience relapsed or refractory disease. … In June 2023, the FDA approved the use of glofitamab for the treatment of patients with relapsed or refractory DLBCL not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma
TAFA-93
go.drugbank.com/drugs/DB05887Experimental, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary artery disease. … TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation
Methsuximide
go.drugbank.com/drugs/DB05246ApprovedMesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.
Synonyms: (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindionPazufloxacin
go.drugbank.com/drugs/DB11774InvestigationalPazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use